For further information on how we select topics for development, please see our page about topic selection ...

We are extremely disappointed that talks to reach a price agreement that would have made advanced breast cancer drug Enhertu available to around 1000 women in England and Wales have not been ...

03 October 2024 This update will cover: Ovarian Function Suppression, Chemotherapy for Advanced Breast Cancer and Biological Therapy for Advanced Breast Cancer For further information on the guideline ...

Crovalimab is recommended, within its marketing authorisation, as an option for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over who weigh 40 kg or more. It is recommended for ...

The Haematological Malignancy Research Network estimate the prevalence of myelofibrosis in the UK to be 3.2 per 100,000 and the incidence is 0.6 per 100,000. This equates to 277 adults diagnosed with ...

There is a commercial arrangement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact keiron.hughes@msd.com for ...

There is a simple discount patient access scheme for crovalimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the technology being ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any interests in the technology being ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

Pembrolizumab (Keytruda, Merck Sharp and Dohme) 'in combination with platinum-containing chemotherapy, as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, is indicated ...